A decade later, a host of new GLP-1s and new indications for existing GLP-1s are being studied, including sleep apnea and diabetic nephropathy
Semaglutide FDA approval was first granted on December 5, 2017, for the brand Ozempic
Supplement stack to complement semaglutide methylcobalamin Beyond the methylcobalamin already in the formulation, several supplements warrant consideration during GLP-1 therapy: Electrolytes: Reduced food and fluid intake can deplete sodium, potassium, and magnesium
Therapeutic paracetamol treatment in older persons induces dietary and metabolic modifications related to sulfur amino acids
CMS guidance states that beneficiary inquiries related to the Medicare GLP-1 Bridge should be directed to 1-800-MEDICARE, while inquiries related to GLP-1 coverage under Part D or coverage for an indication other than weight management remain the plan sponsors responsibility